Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
Small Interfering RNA (siRNA)
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "Small Interfering RNA (siRNA)" in MCE Product Catalog:
8
8 Publications Verification
Synonyms: ALN-PCSsc
Target:
PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related
Research Areas:
Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .
8
Target:
PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related
Research Areas:
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .
4
Research Areas:
Vutrisiran sodium (ALN-TTRsc02 sodium) is a liver-directed small interfering RNA (siRNA). Vutrisiran sodium targets the mRNA of transthyretin (TTR), and is applicable to studies on transthyretin (TTR)-mediated amyloidosis .
Cat. No.: HY-143221
Purity: 95.13%
Target:
Research Areas:
AS-Inclisiran sodium is the antisense of Inclisiran (HY-132591). Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .
Synonyms: SYL1001 sodium
Research Areas:
Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease .
Cat. No.: HY-P10449
CAS No.: 3098205-40-1
Target:
Research Areas:
Cat. No.: HY-143220
Purity: 95.81%
Research Areas:
SS (no Galnac)-Inclisiran sodium is the sense strand of Inclisiran (HY-132591) without GalNAc modification. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. SS (no Galnac)-Inclisiran sodium can be used in cardiovascular disease research .
Synonyms: QPI-1002 sodium
Teprasiran sodium is a small interfering RNA that temporarily inhibits p53-mediated cell death that underlies acute kidney injury (AKI) .
Synonyms: SYL1001
Research Areas:
Tivanisiran (SYL1001) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran is applicable to research related to dry eye disease .
Cat. No.: HY-132595
CAS No.: 1231737-88-4
Synonyms: QPI-1002
Research Areas:
Teprasiran (QPI-1002) is a small interfering RNA that temporarily inhibits p53-mediated cell death that underlies acute kidney injury (AKI) .
Cat. No.: HY-145649A
CAS No.: 2380166-34-5
Synonyms: AD-85481 sodium; ALN-AGT sodium
Research Areas:
Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
